Johnson & Johnson says it is looking to grow within China’s pharmaceuticals industry full-speed ahead and announced plans to new acquisitions in the market.
Reports say J&J’s sales in China last year saw a 10 percent increase from 2012, and the company is now running with its success. J&J CEO Alex Gorsky told reporters that the company now wants to acquire drug and consumer health brands in China to expand current partnerships with Chinese drug makers.
Reports say J&J has placed one of its chairmen in charge of all operations in China to facilitate the company’s direction.
The company added that it is not deterred by recent criticism against Chinese government officials accused of unfairly treating foreign companies. Johnson & Johnson was fined by Chinese competition officials for “monopolistic pricing” of its contact lens operations.
Full content: Fierce Pharma
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Australia’s Major Supermarkets Face Scrutiny Over Profit Margins Amid Rising Prices
Mar 21, 2025 by
CPI
Fired FTC Commissioners Warn of Potential White House Influence Over Mergers
Mar 20, 2025 by
CPI
Dr. Matthew Backus Joins Compass Lexecon as an Affiliate
Mar 20, 2025 by
CPI
UK to Boost Broadband Competition While Capping Openreach Charges, Says Ofcom
Mar 20, 2025 by
CPI
Singapore Competition Watchdog Yet to Receive Formal Notification on Grab-GoTo Merger
Mar 20, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Self-Preferencing
Feb 26, 2025 by
CPI
Platform Self-Preferencing: Focusing the Policy Debate
Feb 26, 2025 by
Michael Katz
Weaponized Opacity: Self-Preferencing in Digital Audience Measurement
Feb 26, 2025 by
Thomas Hoppner & Philipp Westerhoff
Self-Preferencing: An Economic Literature-Based Assessment Advocating a Case-By-Case Approach and Compliance Requirements
Feb 26, 2025 by
Patrice Bougette & Frederic Marty
Self-Preferencing in Adjacent Markets
Feb 26, 2025 by
Muxin Li